Vincent Dunne to lead the next era of international growth for the pharmaceutical contract packaging provider
Wasdell Group, the outsourcing partner for the life sciences industry, has announced the appointment Vincent Dunne as its new Chief Executive Office. Dunne will be responsible for advancing the next era of international growth for the company.
In his new role, Dunne will sit on the company’s board of directors. Dunne succeeds former CEO Martin Tedham, who has taken on a new role as the Chairman of the group.
“We are delighted to have Vincent on board at Wasdell,"
Tedham said. "He brings invaluable experience and expertise to help support the next phases of our expansion," he added.
Tedham said the company has grown over 45% in the last two years and that Wasdell plans to expand its offering even further over the coming years. We could not wish for a better time to strengthen our leadership team," he commented.
Dunne arrived at Wasdell with over 20 years’ experience in senior roles within the pharmaceutical sector, leaving his position at Shire Pharmaceuticals, where he was VP of global materials management and international supply chain for almost a decade.
Commenting on his appointment, Dunne said: “I am thrilled to be joining the Wasdell Group at such a pivotal time of growth and investment, namely the launch of our Dundalk facility, expansion in Swindon and adding new manufacturing capabilities at our Newcastle site.
“Another key focus will be managing existing operations so that we can continue to support customers’ supply chains across the globe with high-quality service and unrivalled lead times.”
As part of the senior management restructure, Daniel Tedham, has also been promoted to Group managing director, taking over responsibilities for sites in Newcastle, Swindon and Burnley, ahead of forecasted growth, which is estimated to increase by 25% by 2020.
The group offers a range of technical, manufacturing, packaging and storage and distribution services and its recent major investments include building its first site outside of the UK, expanding its clinical capabilities across all phases and adding an on-site laboratory at its Newcastle site.